Literature DB >> 10861760

Endothelium-derived factors as paracrine mediators of prostate cancer progression.

G Pirtskhalaishvili1, J B Nelson.   

Abstract

BACKGROUND: Vascular endothelium represents a complex network of cells producing a large number of active substrates affecting physiologic, metabolic, and immunologic properties of the whole organism, as well as particular organs or tissues. The potential influence of endothelium-derived paracrine factors on prostate cancer progression has only begun to be examined.
METHODS: This review summarizes recent literature on endothelium-derived factors, including vasoactive agents, peptide growth factors, cytokines, and colony-stimulating factors, involved in the development and progression of prostate cancer.
RESULTS: Endothelial cells produce an array of active substrates, many of which have been shown to influence prostate cancer growth. Available data demonstrate the positive impact of such molecules as endothelin-1, basic FGF, TGF-beta, IL-6, and IL-8 on prostate cancer progression. Many other endothelium-derived factors NO, IGF, PDGF, IL-1, G-CSF, and GM-CSF (Nitric Oxide, Insulin-Like Growth Factor, Platelet-Derived Growth Factor, Interleukin-1, Granulocyte Colony Stimulating Factor, and Granulocyte-Macrophage Colony Stimulating Factor) are, at best, implicated in prostate cancer growth, and in most cases support cancer progression.
CONCLUSIONS: A better understanding of endothelium-derived factors, as paracrine mediators of prostate carcinogenesis and progression, should aid in the development of novel therapeutic strategies. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861760     DOI: 10.1002/1097-0045(20000615)44:1<77::aid-pros10>3.0.co;2-g

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  34 in total

1.  Mitochondrial regulation of cancer associated nuclear DNA methylation.

Authors:  Cheng-hui Xie; Akihiro Naito; Takatsugu Mizumachi; Teresa T Evans; Michael G Douglas; Craig A Cooney; Chun-Yang Fan; Masahiro Higuchi
Journal:  Biochem Biophys Res Commun       Date:  2007-10-16       Impact factor: 3.575

2.  Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.

Authors:  Primo N Lara; Benjamin Ely; David I Quinn; Philip C Mack; Catherine Tangen; Erik Gertz; Przemyslaw W Twardowski; Amir Goldkorn; Maha Hussain; Nicholas J Vogelzang; Ian M Thompson; Marta D Van Loan
Journal:  J Natl Cancer Inst       Date:  2014-02-24       Impact factor: 13.506

3.  Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis.

Authors:  Longwei Qiao; Yuting Liang; Na Li; Xiaoxia Hu; Dongwei Luo; Junxia Gu; Yaojuan Lu; Qiping Zheng
Journal:  Int J Clin Exp Med       Date:  2015-03-15

4.  The parallel lives of angiogenesis and immunosuppression: cancer and other tales.

Authors:  Gregory T Motz; George Coukos
Journal:  Nat Rev Immunol       Date:  2011-09-23       Impact factor: 53.106

5.  Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.

Authors:  Sun-Jin Kim; Jang Seong Kim; Seung Wook Kim; Seok Joong Yun; Junqin He; Emily Brantley; Dominic Fan; Panja Strickner; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

6.  Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.

Authors:  Snehal G Thakkar; Toni K Choueiri; Jorge A Garcia
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

7.  Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2.

Authors:  Jennifer K Mulligan; Steven A Rosenzweig; M Rita I Young
Journal:  J Immunother       Date:  2010 Feb-Mar       Impact factor: 4.456

Review 8.  Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance.

Authors:  Christine Levesque; Peter S Nelson
Journal:  Cold Spring Harb Perspect Med       Date:  2018-08-01       Impact factor: 6.915

9.  Tumors induce the formation of suppressor endothelial cells in vivo.

Authors:  Jennifer Konopa Mulligan; M Rita I Young
Journal:  Cancer Immunol Immunother       Date:  2010-02       Impact factor: 6.968

10.  The future in advanced prostate cancer: take your partners or is the last dance for me?

Authors:  David I Quinn
Journal:  Rev Urol       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.